Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide

The Journal of Antimicrobial Chemotherapy
Stefanie PannekWinfried V Kern

Abstract

1-(1-Naphthylmethyl)-piperazine (NMP) has been shown to reverse multidrug resistance (MDR) in Escherichia coli overexpressing RND-type efflux pumps but there are no data on its activity in non-fermenters like Acinetobacter. Antimicrobial susceptibility in the absence and presence of NMP and, for comparison, phenyl-arginine-beta-naphthylamide (PAbetaN), another putative efflux pump inhibitor (EPI), was tested in laboratory and mutant strains with differing intracellular dye accumulation and expression of adeB, and in clinical isolates of Acinetobacter baumannii. Based on a 4-fold or greater MIC reduction, the effects of both EPIs at low concentrations (25 mg/L) were limited. PAbetaN had a highly selective action on the reduction in the MIC of rifampicin and clarithromycin. At a higher concentration of the putative EPIs (100 mg/L), NMP was more active than PAbetaN. This effect was not limited to strains with adeB overexpression, but affected the susceptibility to linezolid, chloramphenicol and tetracycline most, and was enhanced in clinical isolates with reduced fluoroquinolone susceptibility. NMP can partially reverse MDR in A. baumannii and differs substantially in its activity from that of PAbetaN.

References

Feb 24, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L FierobeJ M Desmonts
May 3, 2003·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Maria Virginia Villegas, Alan I Hartstein
May 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carl UrbanJames J Rahal
Sep 10, 2004·The Journal of Antimicrobial Chemotherapy·Paul G HigginsHarald Seifert
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Jürgen A Bohnert, Winfried V Kern
Jul 6, 2005·Trends in Molecular Medicine·Jean-Marie PagèsJacques Barbe
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Xian-Zhong SuTomofusa Tsuchiya

❮ Previous
Next ❯

Citations

Dec 13, 2006·Nature Biotechnology·Prabhavathi Fernandes
Jun 15, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nina ChristiansenNiels Frimodt-Møller
Jan 8, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ana Mavri, Sonja Smole Možina
Oct 29, 2009·The Journal of Antimicrobial Chemotherapy·Sasitorn ChusriJulian Davies
Mar 23, 2010·The Journal of Antimicrobial Chemotherapy·Laura J V PiddockSimon Gibbons
Aug 19, 2009·Antimicrobial Agents and Chemotherapy·James J VecchioneJason K Sello
Apr 11, 2007·Antimicrobial Agents and Chemotherapy·Anton Y PelegDavid L Paterson
Dec 22, 2010·Antimicrobial Agents and Chemotherapy·Sébastien CoyneBruno Périchon
Aug 15, 2009·Drugs·Xian-Zhi Li, Hiroshi Nikaido
Dec 6, 2008·Folia Histochemica Et Cytobiologica·Piotr WieczorekElzbieta Tryniszewska
Jul 12, 2013·Transactions of the Royal Society of Tropical Medicine and Hygiene·C GomesJ Ruiz
Jun 19, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J-R SunT-S Chiueh
Jan 31, 2015·International Journal of Environmental Research and Public Health·Jody L AndersenManuel F Varela
Jan 8, 2013·International Journal of Food Microbiology·Ana Mavri, Sonja Smole Možina
Jun 17, 2009·Journal of Medical Microbiology·Yagang ChenLanjuan Li
Mar 1, 2012·Journal of Medical Microbiology·Ana Mavri, Sonja Smole Možina
May 23, 2015·Frontiers in Microbiology·Timothy J Opperman, Son T Nguyen
Jun 23, 2016·Canadian Journal of Microbiology·Sirawit PagdepanichkitRungtip Chuanchuen
Nov 3, 2016·Expert Opinion on Drug Metabolism & Toxicology·Sandrine AlibertJean-Marie Pagès
Feb 24, 2017·International Journal of Molecular Sciences·Zhaohui NiYongqun He
Jun 10, 2015·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Ming-Feng LinChung-Yu Lan
Jul 14, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·João AnesSéamus Fanning
Aug 29, 2013·Journal of the Science of Food and Agriculture·Muhammad Aqeel AshrafMuhammad Abdur Rehman
Sep 11, 2018·Expert Opinion on Drug Discovery·Paula BlancoManuel Alcalde-Rico
Mar 20, 2015·Clinical Microbiology Reviews·Xian-Zhi LiHiroshi Nikaido
Apr 21, 2019·Medicinal Research Reviews·Andraž LamutTihomir Tomašič
Jan 19, 2007·The Journal of Antimicrobial Chemotherapy·Abdallah MahamoudJean-Marie Pagès

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.